33 min listen
Unbelievable Nonprofit Bet on Biomarker Pays off for Parkinson’s ??? (news)
Unbelievable Nonprofit Bet on Biomarker Pays off for Parkinson’s ??? (news)
ratings:
Length:
27 minutes
Released:
Apr 18, 2023
Format:
Podcast episode
Description
A Decade+ Investment Pays off with Parkinson’s Biomarker Discovery
In 2010, the Michael J. Fox Foundation made a BIG bet on investing in researching a biomarker for Parkinson’s Disease (PPMI project). On April 12th it was announced that the bet paid off.
Researchers announced that with the α-synuclein seeding amplification assay (αSyn-SAA), they now have a tool capable of detecting abnormal alpha-synuclein, a key pathology in Parkinson's disease (PD). The breakthrough marks a significant shift in understanding, diagnosing, and treating PD. The assay was validated with 93% accuracy and promises to enable earlier diagnoses, targeted treatments, and more efficient drug development. Efforts are underway to develop αSyn-SAA for the widespread use and optimize it to measure the amount of alpha-synuclein present, potentially through blood draws or nasal swabs. This development holds tremendous potential for transforming research and care for those living with Parkinson's disease.
Read more ➝
Summary
Nonprofit praises automatic expungement program that aims to help millions | FOX 17
Donations Decline for the First Time Since 2012, Fundraising Effectiveness Project Data Shows | NonProfit PRO
These startups and nonprofits are keeping the abortion pill accessible | Fast Company
Sponsored: Looking for trusted nonprofit consultants in New York - or California? Nonprofit.ist has you covered.
In 2010, the Michael J. Fox Foundation made a BIG bet on investing in researching a biomarker for Parkinson’s Disease (PPMI project). On April 12th it was announced that the bet paid off.
Researchers announced that with the α-synuclein seeding amplification assay (αSyn-SAA), they now have a tool capable of detecting abnormal alpha-synuclein, a key pathology in Parkinson's disease (PD). The breakthrough marks a significant shift in understanding, diagnosing, and treating PD. The assay was validated with 93% accuracy and promises to enable earlier diagnoses, targeted treatments, and more efficient drug development. Efforts are underway to develop αSyn-SAA for the widespread use and optimize it to measure the amount of alpha-synuclein present, potentially through blood draws or nasal swabs. This development holds tremendous potential for transforming research and care for those living with Parkinson's disease.
Read more ➝
Summary
Nonprofit praises automatic expungement program that aims to help millions | FOX 17
Donations Decline for the First Time Since 2012, Fundraising Effectiveness Project Data Shows | NonProfit PRO
These startups and nonprofits are keeping the abortion pill accessible | Fast Company
Sponsored: Looking for trusted nonprofit consultants in New York - or California? Nonprofit.ist has you covered.
Released:
Apr 18, 2023
Format:
Podcast episode
Titles in the series (100)
148: How We Won the H-1B Lottery: We interviewed our own Technical Creative Director, Ann Nguyen about her five-year journey of getting an H-1B finally a work-sponsored visa. This long process involved a lot of work, paper, patience and of course, luck. This podcast conversation walks th... by Using the Whole Whale - A Nonprofit Podcast